Beatrice Lopez, NP
Nurse Practitioner · Ligonier, INNPI 1184813693
Payments from drug & device makers
Across 109 payments — averaging $22.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$512
- Novo Nordisk$373
- Bayer$169
- GSK$168
- AstraZeneca$133
- Paratek Pharmaceuticals, Inc.$125
- plus $981 from 19 others
What the payments were for
- Food & beverage$2,450100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 20 | $512 |
| Novo Nordisk | 15 | $373 |
| Bayer | 4 | $169 |
| GSK | 6 | $168 |
| AstraZeneca | 8 | $133 |
| Paratek Pharmaceuticals, Inc. | 1 | $125 |
| Lilly USA, LLC | 7 | $117 |
| Axsome Therapeutics, Inc. | 5 | $106 |
| Xeris Pharmaceuticals, Inc. | 6 | $98 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $88 |
| Boehringer Ingelheim | 5 | $88 |
| Abbott | 4 | $81 |
| Pfizer | 5 | $79 |
| Exact Sciences | 4 | $61 |
| Lundbeck LLC | 3 | $45 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Amneal Pharmaceuticals LLC | 1 | $27 |
| Insulet Corporation | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Johnson & Johnson | 1 | $20 |
| Dexcom, Inc. | 1 | $19 |
| Harmony Biosciences LLC | 1 | $18 |
| Merck | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,461 in reported general payments places this provider in the 85th percentile of 2,724 nurse practitioner providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 225 | $160,948 |
| JardianceEmpagliflozin | 116 | $118,317 |
| TrulicityDulaglutide | 50 | $84,805 |
| EliquisApixaban | 75 | $78,378 |
| OzempicSemaglutide | 42 | $54,763 |
| JanuviaSitagliptin Phosphate | 57 | $49,880 |
| XareltoRivaroxaban | 39 | $37,050 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $19,574 |
| LinzessLinaclotide | 27 | $19,041 |
| TrintellixVortioxetine Hydrobromide | 13 | $18,016 |
| MounjaroTirzepatide | 15 | $15,811 |
| FarxigaDapagliflozin Propanediol | 16 | $14,154 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 16 | $13,364 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $12,849 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $12,208 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $168 | $173,797249 claims |
| Boehringer IngelheimJardiance, Tradjenta | $88 | $129,834132 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Olanzapine | $117 | $101,62192 claims |
| PfizerEliquis | $79 | $78,37875 claims |
| Novo NordiskOzempic | $373 | $54,76342 claims |
| MerckJanuvia | $13 | $49,88057 claims |
| Johnson & JohnsonXarelto | $20 | $37,05039 claims |
| AstraZenecaFarxiga, Symbicort | $133 | $20,25939 claims |
| AbbVieLinzess | $512 | $19,04127 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $88 | $18,01613 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $27 | $2,361278 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 nurse practitioner providers in Indiana.
Other nurse practitioner in Ligonier
- Kristi OrbaughIndianapolis$1.3M
- Kimberly EadsPlainfield$302K
- Sean GoddardFort Wayne$180K
- Kacy RogersIndianapolis$77K
- Kristine TaylorFort Wayne$69K
- Brittany SavageIndianapolis$51K
- Monica HaugerTrafalgar$47K
- Rhonda HettingerClarksville$38K
- Jennifer MaahsIndianapolis$36K
- Amber MillerLawrenceburg$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.